

NOVEL
MEDICINES
PLATFORM

NMP

Transparency Solidarity Sustainability



WHO Europe's Access to Novel Medicines Platform:
ISPOR Europe 13 November 2023, Copenhagen, Denmark

Dr Sarah Garner
Senior Policy Advisor,
Access to Medicines and Health Products, WHO Europe

The role of WHO

The WHO secretariat will focus on:

1. Act as a neutral convenor for the multi stakeholder collaboration, bringing together the Member States, non-State actors and other partner organizations, ensuring equal representation and voice;
2. Facilitate the interactions and co-ordinate any technical work that is prioritized by the working groups;
3. Support the stakeholders in prioritizing activities and concrete actions to take forward.



Aim:

To identify concrete actions, including pilot proposals, to improve affordable and equitable patient access to effective, novel, high-cost medicines in the Region

Objectives:

1. to establish a collaboration mechanism to promote dialogue and knowledge exchange between Member States and with non-State actors, other partners and stakeholders to identify concrete actions to improve patient access to effective, novel, high-cost medicines
2. to agree on actions to improve **transparency** in order to build trust, promote collaboration, enable horizon scanning, and develop indicators to facilitate accountability and corrective actions
3. to strengthen voluntary collaborations that focus on **solidarity** to achieve patient access, including evidence generation, demand aggregation, procurement and management of the life-cycle of medicines
4. to develop principles (including for payment, pricing, health technology assessment and reimbursement) that recognize the need for **sustainability** of health systems and industry, and enable risk sharing and good governance of markets, including how to address market failures and unmet needs
5. to identify policy options for sustainable innovation and access to **novel antimicrobials**, including a review of incentive co-ordination mechanisms for enabling sustainable research and development and the development of access principles (including for payment, pricing, health technology assessment and reimbursement).

4 NMP working groups

WG1 TRANSPARENCY

Chair: Francis Arickx
Advisor/ Head of
the directorate
Pharmaceutical Policy
RIZIV-INAMI, Belgium.

WG1 Face to face meeting
5-6 December 2023,
Brussels, Belgium.

WG2 SOLIDARITY

Chair: Jakub Dvořáček
Deputy Minister of
Health Czechia.

WG2 Face to face
meeting 12-13 October
2023, Prague, Czechia.

WG3 SUSTAINABILITY

Chair: Meindert Boysen,
Head of International
Affairs - National Institute
for Health and Care
Excellence, UK.

WG3 Face to face meeting
12-13 March 2024,
Manchester, UK.

WG4 NOVEL ANTIMICROBIALS

Chair: Malin Grape,
Ministry of Health and
Jenny Hellman, Public
Health Agency of
Sweden.

WG4 Face to face
meeting April/May 2024
TBC, Stockholm, Sweden.

NMP Platform-wide convention, hosted by WHO Europe, 27-28 June 2024 TBC, Copenhagen, Denmark

NOVEL
MEDICINES
PLATFORM

NMP

Transparency Solidarity Sustainability



**World Health
Organization**

European Region

Thank you and over to the panel

<https://www.who.int/europe/groups/the-novel-medicines-platform>

NOVEL
MEDICINES
PLATFORM

NMP

Transparency Solidarity Sustainability



**World Health
Organization**


European Region

Back Up



Background: The Oslo Medicines Initiative 2020-2022

- *Solidarity, Transparency, Sustainability*
- The objectives were
 - to create a neutral platform
 - Reshape political discourse
 - Create partnerships to build a movement for change
- The OMI heard from, consulted and discussed with key stakeholders: governments and payers, private sector and civil society
- Technical webinars and 11 Reports with policy considerations
- WHO/Europe Statement at Regional Committee
Tel Aviv, September 2022 to establish the WHO/Europe Access to Novel Platform



WG 1 upcoming 5-6 December 2023, Brussels, Belgium

Aims and Objectives

To agree on actions to improve transparency in order to build trust, promote collaboration, enable horizon scanning, and develop indicators to facilitate accountability and corrective actions.

- agreement on what information can be made more transparent, in accordance with the framework set out in resolution WHA72.8; and
- identification of indicators to assess patient access to effective, novel, high-cost medicines, and exploring approaches to improve and standardize their collection, analysis and use.

Aims and Objectives

To strengthen voluntary collaborations that focus on **solidarity** to achieve patient access, including evidence generation, demand aggregation, procurement and management of the lifecycle of medicines:

- collaboration for the accrual, evaluation and use of evidence of clinical and economic value across the lifecycle of novel effective, high-cost medicines;
- a feasibility exercise to explore the scale-up of existing voluntary efforts to pool demand and support joint purchasing and joint negotiation of novel effective, high-cost medicines.

WG2 Meeting, 12-13 October, Prague, Czechia

The WG2: **Solidarity** first kick-off meeting was 12-13 October in Prague, Czechia:

- The Chair was Chair Jakub Dvořáček, the Deputy Minister of Health, Czechia and Vice-chairs were Yann Le Cam, EURORDIS and Neil Mulcock, EFPIA.
- Total participation included 12 MS (including attendees for technical presentations and observers such as Chairs of WG1 and WG3), 3 patient organizations, 7 partner organizations and 5 industry organizations.
- The meeting consisted of technical presentations, knowledge sharing, plenary discussions and discussions in small breakout groups.



WG 3 upcoming 12-13 March 2024, Manchester, UK

Aims and Objectives

To develop principles (including for payment, pricing, health technology assessment and reimbursement) that recognize the need for sustainability of health systems and industry, and enable risk sharing and good governance of markets, including how to address market failures and unmet needs:

- reviewing affordable pricing principles;
- determining the key elements needed for governance of the market, including social contracts and the role of corporate social governance.


Aims and Objectives

To identify policy options that facilitate sustainable innovation and access to novel antimicrobials.

- A review of incentive co-ordination mechanisms for enabling sustainable research and development;
- Development of access principles (including for payment, pricing, health technology assessment and reimbursement).



NMP Working Groups



- Nominations by Member States (MS) and registered entities/partners
- MS Chair
- Vice-chairs from Non-State actors and other partners (2 vice-chairs, 1 from NGO/ partner and 1 from industry)
- WHO will ensure appropriate and equal representation across
 - eligible entities (Member States, non-State actors and other partners),
 - geographical locations and income levels
 - gender.